Ponsegromab

Ponsegromab
Monoclonal antibody
Type?
TargetGDF-15
Clinical data
Other namesPF-06946860
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
UNII

Ponsegromab (PF-06946860) is a monoclonal antibody that works as a GDF-15 inhibitor. It is developed by Pfizer for cancer cachexia.[1][2][3][4][5]

In September 2024, Pfizer disclosed that ponsegromab led to significant body weight increases in patients with non-small cell lung cancer, pancreatic cancer, or colorectal cancer in a phase 2 clinical trial.[6]

References

  1. ^ Nishie, Kenichi; Nishie, Tomomi; Sato, Seiichi; Hanaoka, Masayuki (September 2023). "Update on the treatment of cancer cachexia". Drug Discovery Today. 28 (9) 103689. doi:10.1016/j.drudis.2023.103689. PMID 37385369. S2CID 259294809.
  2. ^ Roeland, E.J.; Yennu, S.; Del Fabbro, E.; Buckeridge, C.; Thayer, K.M.; Collins, S.M.; Lubaczewski, S.L.; Wang, E.Q.; Calle, R.A. (September 2021). "1696TiP Phase Ib study to assess the effect of PF-06946860 on appetite following subcutaneous administration in patients with anorexia and advanced cancer". Annals of Oncology. 32: S1185. doi:10.1016/j.annonc.2021.08.1668.
  3. ^ Crawford, Jeffrey; Lubaczewski, Shannon L; Tarachandani, Anil; Harrington, Magdalena A; Weng, Yan; Qiu, Ruolun; Collins, Susie M; Rossulek, Michelle I; Revkin, James H (1 June 2023). "Phase 2 study to assess the efficacy, safety, and tolerability of the GDF-15 inhibitor ponsegromab in patients with cancer cachexia". Journal of Clinical Oncology. 41 (16_suppl) TPS12147. doi:10.1200/JCO.2023.41.16_suppl.TPS12147.
  4. ^ Crawford, Jeffrey; Calle, Roberto A.; Collins, Susie M.; Weng, Yan; Lubaczewski, Shannon L.; Buckeridge, Clare; Wang, Ellen Q.; Harrington, Magdalena A.; Tarachandani, Anil; Rossulek, Michelle I.; Revkin, James H. (14 April 2023). "Abstract CT108: First-in-patient study of the GDF-15 inhibitor ponsegromab in patients with cancer and cachexia: Safety, tolerability, and exploratory measures of efficacy". Cancer Research. 83 (8_Supplement) CT108. doi:10.1158/1538-7445.AM2023-CT108. S2CID 258165004.
  5. ^ Talbert, Erin E.; Guttridge, Denis C. (May 2022). "Emerging signaling mediators in the anorexia–cachexia syndrome of cancer". Trends in Cancer. 8 (5): 397–403. doi:10.1016/j.trecan.2022.01.004. PMC 9035074. PMID 35190301.
  6. ^ "Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia | Pfizer". www.pfizer.com. Retrieved 2024-10-28.


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.